Our differentiated therapies have the potential to set new standards for efficacy and patient response rates across various difficult-to-treat cancers. The company was established in 2017 based on seminal research at the Hebrew University of Jerusalem and the University of Rijeka. Our technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies (mAbs) and antibody-drug-conjugates (ADCs).
Nectin Therapeutics has an established, scientific and management team with deep experience in oncology R&D, successful track record building biotech companies and developing innovative therapies. Nectin Therapeutics is a venture-backed, privately held company, funded by our partners at aMoon Fund, Peregrine Ventures, and Integra Holdings.